Avexa ..Vorläufige PIII (16week) Daten noch in Juni !!! - 500 Beiträge pro Seite

[BrauchGeld]

Hier könnte sich ein Einstieg lohnen ich zumindest bin schon seit 0,10 A$ dabei !!

Macht am besten euere Hausaufgaben selbst !


Was sich noch positiv auf den Kurs auswirken könnte :

Vermarktungspartner für Apricitabine

Tibotec (Johnson&Johnson) hat 6 monate Zeit den Deal(betrifft nicht Apricitabine in PIII) mit Avexa einzugehen


Avexa (AVX.AX)

Marktkap : 91,9 Mio A$
Cash : 30 Mio A$ << reicht für weitere 12 Monate
Kurs : 0,135 A$


Its time to focus on upcoming milestones

The next milestone to watch is the release of 16-week data from the first of two Phase III
trials of apricitabine (ATC) in 2QCY09. We believe this newsflow is critical in the short term,
and the data to date lends confidence to our view that the trials will report positive results.


Signs option agreement for pre-clinical HIV program, a small positive step forward
AVX has entered into a six-month, worldwide exclusive option agreement with Tibotec
Pharmaceuticals (a Johnson & Johnson company) relating to its HIV integrase program (preclinical).
The option provides an exclusivity period for the two companies to formalise a
licensing agreement while Tibotec continues to review the program portfolio.


Upcoming milestones :

2QCY09 Release of 16-week data from first Phase III ATC clinical trial Positive

4QCY09 Phase IIb 144 week final data analysis Positive

2QCY10 Complete enrolment of first Phase III study Positive

4QCY10 Phase III (first trial) week 24 data available Positive

1QCY11 Potential filing from 24 week data in some jurisdictions Major Positive

[BrauchGeld]

Sollte Tibotec den Deal eingehen dürften Upfront-Zahlungen im zweistelligen Millionbereich fällig sein !

Avexa signs option agreement for HIV program

Melbourne, Australia, 4th May 2009: Biotechnology company Avexa Limited (‘Avexa’) (ASX:AVX) today
announced that it has entered into a 6 month, worldwide exclusive option agreement with Tibotec
Pharmaceuticals relating to its HIV integrase program. The option provides an exclusivity period for the two
companies to formalize a collaborative research and license agreement while Tibotec continues to review the
Avexa HIV-1 Integrase Inhibitor drug program portfolio.
"We are excited and very encouraged by the results of the preliminary evaluation of HIV-1 Integrase Inhibitors
that Avexa and Tibotec have undertaken to date.” stated Dr Julian Chick. "One of the major benefits of
working with Tibotec is the breadth of experience and resources in the anti-HIV drug field that they bring to
bear which may enable us to significantly accelerate our programs.”
Over the past 5 months the two companies have been working collaboratively to evaluate compounds from
Avexa’s HIV Integrase program. If they enter into a research collaboration and license agreement, Tibotec
and Avexa will continue to collaborate, harnessing the medicinal chemistry and the in-vitro resources of both
companies to support and accelerate the Avexa HIV integrase program. Treatment of HIV infected patients
with the only currently approved anti-HIV integrase drug, results in the selection of viruses that are resistant to
that drug. Avexa's lead anti-integrase compounds are able to inhibit these integrase inhibitor-resistant HIV
because they interact with the HIV-integrase in a different way to the marketed drug.
“Tibotec has considerable HIV drug development experience and of course this would benefit our programs in
their development. We look forward to our great working relationship with Tibotec and hope that we can
conclude a collaboration and license agreement in the near future” stated Avexa CEO Dr Julian Chick.”

[BrauchGeld]

Tja wieder so ein timing wie auch immer die PIII Daten sind positiv und damit hat Avexa noch bessere Chanen einen guten Partner zufinden !

Würde den Tag heute als typischen "Sell on good news " werten .